Role of Sodium-Glucose Cotransporter-2 Inhibitors in Readmissions for Congestive Heart Failure
Joseph Keryakos1★, Robert Kranz1, Rachel Propst1, Jena Rathert1, Kelli Semerad1★ Corresponding author
- 1Department of Pharmacy Practice, South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, South Dakota, USA.
CORRESPONDENCE
Joseph Keryakos
Department of Pharmacy Practice, South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, South Dakota, USA.
Received: 17-05-2021; Revised: 29-06-2021; Accepted: 26-07-2021.
Volume 13, Issue 3 · pp. 257–261 · PUBLISHED · DOI: 10.5530/jyp.2021.13.52
ABSTRACT
Background: Patients with type II diabetes are at major risk for cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) have demonstrated benefit for these patients. The purpose of this study is to determine whether SGLT-2 inhibitors significantly reduce heart failure readmission rates and improve outcomes in patients with congestive heart failure (CHF).Methods:Patient data was pulled on CHF patients with an active prescription for an SGLT-2 inhibitor, and it was analyzed using Fischer’s Exact tests and two-tailed t-tests. The primary outcome was a 6-month hospital readmission rate due to CHF while taking SGLT-2 inhibitors. Secondary outcomes included 6-month all-cause hospital readmissions, renal function as measured by an estimated glomerular filtration rate change between admissions, mortality rates, and ejection fraction. Results: Of the 138 patients that met inclusion criteria for the first admission, the 6-month all-cause readmission rate for CHF patients still taking SGLT-2 inhibitors at readmission was 21 percent vs 16 percent (p=0.6) for the control group not taking SGLT-2 inhibitors. The 6-month CHF readmission rate in patients taking SGLT-2 inhibitors was 7.2 percent, and a CHF specific readmission rate was not collected for the control group. In patients with an eGFR less than 90, the average eGFR for the SGLT-2 group declined slightly but was not significant between patients at first admission and those with readmission (p=0.21). Conclusion: The use of SGLT-2 inhibitors in patients with CHF did not change the overall hospital readmission rate; however, larger randomized controlled trials are needed for further evaluation of the potential benefit.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Keryakos, J., Kranz, R., Propst, R., Rathert, J., & Semerad, K. (). Role of Sodium-Glucose Cotransporter-2 Inhibitors in Readmissions for Congestive Heart Failure. Journal of Young Pharmacists, 13(3), 257–261. https://doi.org/10.5530/jyp.2021.13.52